Mezagitamab (TAK-079): A Comprehensive Report on an Investigational Anti-CD38 Monoclonal Antibody

1. Executive Summary

Mezagitamab (TAK-079) is an investigational, fully human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody targeting the CD38 protein. It is being developed primarily by Takeda, following its initial discovery using BioInvent's n-CoDeR® platform, for the treatment of various autoimmune diseases and hematologic malignancies where CD38-expressing cells play a pathogenic role. The drug is administered via subcutaneous injection.

The primary mechanism of action involves binding to CD38 on the surface of plasmablasts, plasma cells, Natural Killer (NK) cells, and activated T and B lymphocytes. This binding leads to the depletion of these cells through multiple effector functions, including Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC), and allosterically inhibits the enzymatic activity of CD38.

Mezagitamab's most advanced clinical program is for Primary Immune Thrombocytopenia (ITP). Positive topline results from the Phase 2b trial (NCT04278924) demonstrated dose-dependent, rapid, and sustained platelet responses, prompting progression to a global Phase 3 trial (NCT06722235). The drug is also under investigation for Myasthenia Gravis (Phase 2 completed with some positive signals), Relapsed/Refractory Multiple Myeloma (Phase 1b showing promising activity), Systemic Lupus Erythematosus (Phase 1b/2 with modest clinical efficacy despite pharmacodynamic effects), and IgA Nephropathy (Phase 1/2 ongoing).

Across various studies, mezagitamab has generally been reported as well-tolerated, with a manageable adverse event profile. The subcutaneous route of administration and a potentially favorable safety profile, particularly concerning infusion-related reactions and certain hematologic toxicities compared to some intravenous anti-CD38 therapies, are notable features.

Mezagitamab has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for both ITP and Myasthenia Gravis, as well as Fast Track Designation for chronic/persistent ITP. Clinical development programs are active in Europe and Japan, indicating ongoing engagement with the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) respectively. The continued development of mezagitamab holds promise for new therapeutic options in several conditions with unmet medical needs.

2. Introduction to Mezagitamab (TAK-079)

Mezagitamab, also known by its development code TAK-079, is an investigational biopharmaceutical agent currently undergoing extensive clinical evaluation for a range of immunological and hematological disorders. This section provides foundational information regarding its identification, classification, therapeutic rationale, and development history.

2.1 Drug Identification

Mezagitamab is identified by several key descriptors:

International Nonproprietary Name (INN): Mezagitamab.[1]
Development Codes: Predominantly TAK-079. An alias, TAK-169, has also been noted, though TAK-079 is the most consistently used identifier in recent documentation.[2]
DrugBank ID: DB16370 [User Query].
CAS Number: 2227490-52-8.[2]
Molecular Weight: Approximately 145 kDa as reported by ApexBio [2] and 143.7 kDa by MedChemExpress.[3] This minor variance (around 1%) is typical for large biologic molecules and can be attributed to differences in analytical methodologies or slight variations in post-translational modifications such as glycosylation. Such discrepancies are common in the characterization of monoclonal antibodies and do not typically raise concerns about the fundamental identity of the molecule.

2.2 Drug Type and Class

Mezagitamab is classified as:

Type: A biotechnology-derived product (Biotech) [User Query].
Class: A fully human IgG1λ (Immunoglobulin G1 lambda) anti-CD38 monoclonal antibody.[2] It is further characterized as a non-agonistic antibody.[7]

The IgG1λ isotype is a significant design choice. IgG1 antibodies are known for their robust effector functions, including the ability to mediate ADCC through engagement of Fcγ receptors on immune cells like NK cells, and to activate the complement system, leading to CDC. These functions are integral to mezagitamab's intended mechanism of depleting CD38-expressing target cells. The "fully human" designation implies that the antibody's protein sequences are derived from human genetic material, which is intended to minimize its immunogenicity and reduce the likelihood of patients developing anti-drug antibodies (ADAs) that could impair efficacy or cause adverse reactions.

2.3 Therapeutic Rationale and Background

The therapeutic strategy behind mezagitamab centers on targeting the CD38 protein. CD38 is a type II transmembrane glycoprotein with dual roles as a receptor and an ectoenzyme involved in calcium signaling and NAD metabolism.[5] It is highly expressed on terminally differentiated B lymphocytes, namely plasmablasts and plasma cells, which are the primary producers of antibodies.[5] CD38 is also found on NK cells, and at lower densities on activated T and B lymphocytes, and other hematopoietic cells.[7]

In numerous autoimmune diseases, such as ITP, Myasthenia Gravis, and SLE, pathogenic autoantibodies produced by plasma cells play a crucial role in disease initiation and propagation.[5] Similarly, in hematologic malignancies like multiple myeloma, malignant plasma cells overexpress CD38.[7] Consequently, depleting these CD38-positive cells represents a direct approach to reducing autoantibody levels in autoimmune conditions or eliminating cancerous cells in myeloma. The expression of CD38 on other immune cells like NK cells and activated T cells suggests that mezagitamab's effects may extend beyond simple antibody depletion, potentially offering broader immunomodulation. This wider impact could be therapeutically advantageous in diseases with complex immune dysregulation but also necessitates careful monitoring for potential off-target immunological effects.

2.4 Developer Information

The development of mezagitamab is a collaborative effort:

Primary Developer: Takeda (through its entities Takeda Pharmaceutical Co., Ltd., Takeda Development Center Americas, Inc., and Millennium Pharmaceuticals, Inc.) is leading the clinical development and holds primary commercialization rights.[6]
Origin of Antibody: Mezagitamab was originally identified from the proprietary n-CoDeR® antibody library of BioInvent International AB.[4]
Licensing Agreements: Takeda's development of mezagitamab is based on a sublicense from XOMA Corporation. XOMA's rights stem from a long-standing cross-licensing agreement with BioInvent that covers the n-CoDeR® library and XOMA's bacterial protein expression technology. BioInvent is entitled to milestone payments from Takeda, contingent on development progress, such as the $1 million USD payment triggered by the initiation of the Phase 3 trial in ITP.[4] This multi-entity collaboration is characteristic of the biopharmaceutical industry, leveraging specialized expertise. BioInvent's discovery capabilities are complemented by Takeda's extensive resources for late-stage clinical development, regulatory affairs, and global commercialization. The progression of mezagitamab to Phase 3 trials serves as a validation of BioInvent's n-CoDeR® platform.

Table 1: Mezagitamab (TAK-079) - Key Identifiers and Properties

Identifier/Property	Value/Description	Source Snippet(s)
INN	Mezagitamab	1
Development Code(s)	TAK-079 (primary), TAK-169 (alias)	2
DrugBank ID	DB16370	[User Query]
CAS Number	2227490-52-8	2
Molecular Weight	Approx. 143.7 kDa - 145 kDa	2
Drug Type	Biotech	[User Query]
Drug Class	Fully human IgG1λ anti-CD38 monoclonal antibody, non-agonistic	2
Primary Developer(s)	Takeda (Origin: BioInvent, via XOMA license)	4
Target Antigen	CD38 (ADP-ribosyl cyclase 1)	2
Host Cell for Prod.	CHO (Chinese Hamster Ovary) cells	2
Administration Route	Subcutaneous (SC) injection	3

3. Mechanism of Action

Mezagitamab exerts its therapeutic effects by targeting the CD38 protein, a multifaceted cell surface molecule. Its mechanism involves direct binding to CD38-expressing cells, leading to their elimination, and modulation of CD38's enzymatic functions.

3.1 Target Engagement

Mezagitamab is a fully human, non-agonistic IgG1λ monoclonal antibody that binds with high affinity to human CD38.[3] CD38 is prominently expressed on plasmablasts and plasma cells, the body's primary antibody-producing cells. It is also found on NK cells and, to a lesser extent, on activated T and B lymphocytes, as well as plasmacytoid dendritic cells.[5]

A noteworthy characteristic of mezagitamab, highlighted in preliminary studies, is its potentially more selective binding to CD38 on target cells like myeloma cells, with comparatively less cross-reactivity to CD38 on erythrocytes (red blood cells) and platelets.[16] This differential binding affinity is of considerable clinical interest. CD38 is indeed present on RBCs and platelets, and significant binding by anti-CD38 antibodies to these cells can lead to their premature destruction, resulting in common adverse events such as anemia and thrombocytopenia. An antibody engineered or selected for enhanced affinity to CD38 on pathogenic immune cells or myeloma cells, while relatively sparing these "off-target" blood cells, could theoretically offer an improved hematological safety profile. This would be a clinically meaningful advantage, potentially reducing the need for supportive care or dose modifications due to cytopenias.

3.2 Effector Functions and Cellular Consequences

The binding of mezagitamab to CD38 on target cells initiates several potent immune effector mechanisms, culminating in cell depletion [2]:

Antibody-Dependent Cellular Cytotoxicity (ADCC): The Fc portion of the IgG1 mezagitamab antibody engages Fcγ receptors (primarily FcγRIIIa on NK cells), leading to the lysis of CD38-coated target cells.[3]
Complement-Dependent Cytotoxicity (CDC): The IgG1 Fc region can also activate the classical complement pathway, forming the membrane attack complex on the target cell surface and causing osmotic lysis.[3]
Apoptosis: Mezagitamab may directly induce programmed cell death in CD38-expressing cells.[3]
Antibody-Dependent Cellular Phagocytosis (ADCP): Opsonization of target cells by mezagitamab can facilitate their engulfment and destruction by phagocytic cells, such as macrophages.[16]

Beyond direct cell killing, mezagitamab has been shown to allosterically inhibit the enzymatic activity of CD38.[3] CD38 functions as an ectoenzyme, catalyzing the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) and nicotinamide adenine dinucleotide phosphate (NAADP), which are important second messengers in calcium signaling. It also has NAD+ glycohydrolase (NADase) activity. The clinical relevance of this enzymatic inhibition by mezagitamab, in addition to cell depletion, is an area for further investigation but could contribute to its overall therapeutic effect by modulating cellular metabolism and signaling pathways.

A significant characteristic described for mezagitamab is its non-agonistic nature; it reportedly does not induce CD38-dependent signaling or promote cytokine activation in peripheral blood mononuclear cells (PBMCs) in in vitro assays.[7] This is an important feature for safety, as it suggests a lower intrinsic risk of inducing systemic inflammatory responses or widespread cytokine release syndrome (CRS) often associated with agonistic antibodies or those that strongly activate immune cells. However, it is important to note that in a Phase 1 study involving healthy volunteers, mild, transient CRS was observed, particularly with intravenous administration, which coincided with target cell depletion and moderate increases in inflammatory cytokines.[5] This suggests that while the antibody itself may be non-agonistic, the rapid in vivo lysis of a substantial number of CD38+ cells can, by itself, trigger a secondary inflammatory response and cytokine release. The observation that subcutaneous administration was associated with a lower incidence of CRS [5] is consistent with a more gradual drug absorption and potentially a less abrupt peak of cell killing, thereby mitigating the systemic cytokine surge.

The primary therapeutic outcome of these mechanisms is the depletion of CD38-expressing cells. In autoimmune diseases, this leads to a reduction in plasmablasts and plasma cells, thereby diminishing the production of pathogenic autoantibodies.[5] In hematologic malignancies like multiple myeloma, the objective is the direct elimination of the malignant CD38-positive plasma cells.[16] The combined action of multiple cytotoxic pathways (ADCC, CDC, apoptosis, ADCP) and enzymatic inhibition suggests a robust and potentially resilient mechanism for target cell elimination, which could be advantageous in overcoming resistance mechanisms that might affect any single pathway.

4. Pharmacology

The pharmacological profile of mezagitamab, encompassing its pharmacokinetics (PK) and pharmacodynamics (PD), has been investigated in healthy volunteers and various patient populations. These studies are crucial for understanding its absorption, distribution, metabolism, excretion, and its biological effects on target cells and biomarkers.

4.1 Pharmacokinetics (PK)

The PK of mezagitamab has been characterized primarily through studies in healthy volunteers and is being further assessed in ongoing patient trials.

Healthy Volunteers (Phase 1, Single Ascending Dose Study) [5]:

Intravenous (IV) Administration:
At very low doses (0.0003–0.01 mg/kg), serum concentrations of mezagitamab remained below the lower limit of quantification (LLOQ) of 10 ng/mL, indicating rapid clearance or distribution.
Following a 0.03 mg/kg IV infusion, the mean maximum observed serum concentration (Cmax) was 21.4 ng/mL (coefficient of variation [CV] 39%), with a median time to Cmax (tmax) of approximately 2.09 hours.
At 0.06 mg/kg IV, the mean Cmax increased to 100.4 ng/mL (CV 52%), with a similar median tmax of approximately 2.09 hours.
The increase in Cmax from the 0.03 mg/kg to the 0.06 mg/kg dose (approximately 4.7-fold for a 2-fold dose increase) suggested a greater than dose-proportional exposure in this range.
After IV infusion, serum concentrations typically fell below the LLOQ within 1 to 4 hours, which limited the ability to accurately calculate other PK parameters like half-life or total exposure (AUC) at these low doses.
Subcutaneous (SC) Administration:
At SC doses of 0.03–0.3 mg/kg, serum concentrations were generally below the LLOQ.
At a higher SC dose of 0.6 mg/kg, the mean Cmax was 23.0 ng/mL (CV 67%), achieved at a median tmax of approximately 23.87 hours (range: 7.98–96.02 hours).
The mean area under the curve until the last quantifiable concentration (AUC_last_) for the 0.6 mg/kg SC dose (in 5 of 6 subjects with quantifiable levels) was 90.4 ng·day/mL (CV 92%).
Serum concentrations after the 0.6 mg/kg SC dose typically remained above LLOQ for 3 to 14 days.
When dose-normalized, the Cmax following SC injection was substantially lower than that observed after IV infusion. However, the SC route provided more sustained serum concentrations above LLOQ.

The pharmacokinetic behavior observed in healthy volunteers, particularly the rapid clearance and non-proportional exposure at lower IV doses, is characteristic of target-mediated drug disposition (TMDD). TMDD occurs when a significant fraction of the drug is eliminated through high-affinity binding to its pharmacological target (CD38). At low drug concentrations, this target-binding pathway dominates clearance, leading to non-linear kinetics. As target sites become saturated with increasing doses, clearance shifts towards more conventional, non-specific elimination pathways, and PK tends to become more linear. The SC administration route, with its slower absorption phase, results in a lower Cmax but more prolonged exposure, which can be beneficial for maintaining target engagement and potentially improving the therapeutic window by avoiding high peak concentrations that might be associated with acute side effects. This profile supports the selection of SC administration for ongoing clinical development in patient populations requiring chronic treatment.

Patient Populations:

Systemic Lupus Erythematosus (SLE) Patients (Phase 1b/2): Serum concentrations were measured using a validated electrochemiluminescence immunoassay (LLOQ 5 ng/mL). While PK was a secondary endpoint, specific parameters are not detailed in the available abstracts.[8]
Multiple Myeloma (MM) Patients (Phase 1b): PK was a secondary objective, but detailed parameters are not provided in the preliminary abstract.[16]
ITP Patients (Phase 3 NCT06722235): Serum mezagitamab concentration is a planned secondary outcome, with sampling up to Day 169.[12]
IgA Nephropathy Patients (Phase 1/2 NCT05174221): Serum trough concentrations (Ctrough) are a secondary outcome, measured up to Week 48.[13]

While detailed PK data in patient populations are still emerging, the consistent inclusion of PK assessments across various trials underscores its importance for dose selection and understanding exposure-response relationships.

4.2 Pharmacodynamics (PD)

Pharmacodynamic studies have focused on mezagitamab's effects on target cell populations and relevant biomarkers.

Healthy Volunteers (Phase 1, Single Dose Study) [5]:

IV Dosing:
A dose-dependent reduction in peripheral blood NK cells (CD16+/CD56+) was observed at doses ≥0.003 mg/kg. The 0.06 mg/kg IV dose resulted in a 97–99% reduction from baseline in NK cells by 8 hours post-infusion. The effective dose for 50% of maximum NK cell reduction (ED50) was 0.02 mg/kg, corresponding to an effective concentration (EC50) of 0.01 µg/mL. NK cell counts recovered to baseline levels within 3 to 8 days, depending on the dose.
No comparable acute reductions were noted for RBCs, platelets, granulocytes, total lymphocytes, B cells, or T cell subsets at these IV doses.
SC Dosing:
Dose-dependent reductions in peripheral blood plasmablasts (CD19+CD20dimCD27brightCD38bright) were seen at doses ≥0.1 mg/kg. A >90% reduction in plasmablasts from baseline was achieved with the 0.6 mg/kg SC dose (ED50 0.1 mg/kg; EC50 0.01 µg/mL). The maximum reduction occurred around 48 hours post-dose, with recovery to near baseline taking 22–50 days, in a dose-dependent manner.
Reductions in NK cells mirrored those of plasmablasts with SC dosing (≥0.1 mg/kg), with an ED50 of 0.1 mg/kg and an estimated EC50 of 0.01 µg/mL. NK cell nadir was also at ~48 hours, with recovery taking 4–22 days.
The durability of NK cell reduction was approximately 2–3 times longer with SC administration (e.g., 0.6 mg/kg SC) compared to IV administration (e.g., 0.06 mg/kg IV).
Serum total IgA, IgG, and IgM levels showed reductions of 15–60% following SC doses of ≥0.1 mg/kg. These effects were less pronounced with IV dosing. For SC doses ≥0.3 mg/kg, immunoglobulin levels had not returned to baseline within the 78-day observation period.

These PD findings in healthy subjects confirm potent, dose-dependent depletion of CD38-expressing NK cells and plasmablasts. The SC route demonstrated more sustained cellular depletion and immunoglobulin reduction, reinforcing its selection for further development. The prolonged impact on immunoglobulin levels necessitates careful monitoring for potential immunosuppressive effects and infection risk in long-term patient treatment.

Systemic Lupus Erythematosus (SLE) Patients (Phase 1b/2) [8]:

In patients receiving 45 mg, 90 mg, or 135 mg SC mezagitamab every 3 weeks for 12 weeks:
Median CD38 receptor occupancy (RO) on CD38+ NK cells reached up to 88.4% in the 135 mg group.
Concurrent depletion of these NK cells was up to 90% in the 135 mg cohort.
However, mean reductions in total IgG and specific autoantibodies (anti-dsDNA, anti-ENA) were modest, remaining less than 20% across all dose groups.
Advanced cellular analysis (CyTOF) and type 1 IFN gene signature assessments indicated a "broad immune landscape shift."

In SLE patients, despite achieving high receptor occupancy and significant NK cell depletion, the impact on total IgG and autoantibody levels was limited with the Q3W dosing regimen over 12 weeks. This could suggest that the effect on long-lived plasma cells, the main source of established autoantibodies, was insufficient with this regimen, or that the turnover rate of these antibodies is slow. The observed "broad immune landscape shift" is an intriguing finding that warrants further elucidation.

Multiple Myeloma (MM) Patients (Phase 1b) [16]:

Pharmacodynamic analyses demonstrated dose-dependent saturation of CD38 on target cells and, critically, depletion of bone marrow myeloma cells. This effect was maximal at the 300mg SC dose. This direct evidence of target engagement and elimination of malignant plasma cells within the bone marrow strongly supports the therapeutic rationale for mezagitamab in MM.

Table 2: Summary of Key Pharmacodynamic Effects of Mezagitamab

PD Marker	Study Population	Mezagitamab Dose/Regimen	Observed Effect	Source Snippet(s)
NK Cell Depletion (Peripheral Blood)	Healthy Volunteers	≥0.003 mg/kg IV	Dose-dependent; 97-99% reduction at 0.06 mg/kg. ED50 0.02 mg/kg. Recovery 3-8 days.	5
NK Cell Depletion (Peripheral Blood)	Healthy Volunteers	≥0.1 mg/kg SC	Dose-dependent; >90% reduction at higher doses. ED50 0.1 mg/kg. Recovery 4-22 days. More durable than IV.	5
Plasmablast Depletion (Peripheral Blood)	Healthy Volunteers	≥0.1 mg/kg SC	Dose-dependent; >90% reduction at 0.6 mg/kg. ED50 0.1 mg/kg. Recovery 22-50 days.	5
Serum Immunoglobulin (Total IgA, IgG, IgM) Reduction	Healthy Volunteers	≥0.1 mg/kg SC	15-60% reduction; recovery slow for ≥0.3 mg/kg (beyond 78 days).	5
CD38 Receptor Occupancy (NK Cells)	SLE Patients	Up to 135 mg SC Q3W	Median RO up to 88.4% (135 mg).	8
NK Cell Depletion (Peripheral Blood)	SLE Patients	Up to 135 mg SC Q3W	Up to 90% depletion (135 mg).	8
Total IgG / Autoantibody Reduction	SLE Patients	45, 90, 135 mg SC Q3W	Mean reduction <20% for total IgG and specific autoantibodies.	8
Bone Marrow Myeloma Cell Depletion	RRMM Patients	45-600 mg SC (escalating)	Dose-dependent depletion, maximal at 300mg.	16

5. Clinical Development Program

Mezagitamab is under investigation for several indications where CD38-expressing cells are implicated in disease pathology. The development program spans multiple phases and geographic regions, reflecting a broad therapeutic ambition.

Table 3: Overview of Key Mezagitamab (TAK-079) Clinical Trials

Trial ID (NCT/EudraCT/jRCT)	Phase	Indication	Status (as of latest snippets)	Key Objectives	Est. Participants	Mezagitamab Dosage(s)	Comparator(s)	Key Findings/Current Status Summary	Source Snippet(s)
NCT04278924 (TAK-079-1004)	2b	Primary Immune Thrombocytopenia (Persistent/Chronic)	Active, Not Recruiting (Interim results reported, study ongoing for follow-up)	Safety, Tolerability, Efficacy (platelet response)	41	100mg, 300mg, 600mg SC QW for 8 weeks	Placebo	Positive topline: dose-dependent, rapid, sustained platelet response; well-tolerated. Full results presented ISTH 2024.	6
NCT06722235 (TAK-079-3002) / EU CTIS 2024-514401-54-00 / jRCT2031240667	3	Chronic Primary Immune Thrombocytopenia	Recruiting	Efficacy (durable platelet response), Safety	171	SC (dose based on Ph2)	Placebo	Global Phase 3 initiated based on Ph2b results.	9
NCT06948318 / EUCT2025-521692-31-00	3 (OLE)	Chronic Primary Immune Thrombocytopenia	Not Yet Recruiting (Planned Aug 2025)	Long-term safety and efficacy (Continuation for NCT04278924 & NCT06722235)	150	SC Mezagitamab	Open-label	Continuation study for prior ITP trials.	10
NCT04159805 / EudraCT 2019-003383-47 (TAK-079-1005)	2	Generalized Myasthenia Gravis	Completed	Safety, Tolerability, Efficacy (MG scales, autoantibodies)	36	300mg, 600mg SC QW for 8 weeks	Placebo	Completed. 300mg showed some efficacy signals (MGC, anti-AChR Ab). Well-tolerated.	15
NCT03439280	1b	Relapsed/Refractory Multiple Myeloma (RRMM)	Completed/Data Reported	Safety, MTD, Efficacy (ORR)	31 (28 evaluable for early report)	45mg, 135mg, 300mg, 600mg SC (escalating schedule)	Single-agent	ORR 43% in pts with ≥4 cycles. Well-tolerated. PD showed BM myeloma cell depletion.	10
Not specified (SLE study)	1b/2	Systemic Lupus Erythematosus (Moderate to Severe)	Completed/Data Reported	Safety, Tolerability, PK, PD, Efficacy (SLEDAI, CLASI)	22 (17 on Mezagitamab)	45mg, 90mg, 135mg SC Q3W for 12 weeks	Placebo	Well-tolerated. Modest clinical efficacy. PD effects on NK cells, <20% Ig/autoAb reduction.	8
NCT05174221 (TAK-079-1006) / EudraCT 2021-005023-20 / jRCT2011220009	1/2	Primary IgA Nephropathy	Active, Not Recruiting (Enrollment complete)	Safety, Tolerability, PK, PD, Efficacy (UPCR)	16	SC Mezagitamab (QW x8wks, then Q2W x16wks)	Single-arm / Open-label	Ongoing, est. completion Mar 2026.	10
NCT06963827 / EUCT2025-520825-19-00	3	Primary IgA Nephropathy	Not Yet Recruiting (Planned Aug 2025)	Efficacy, Safety	Not specified	SC Mezagitamab (Combination therapy)	Placebo	Planned Phase 3 trial.	10
Not specified (RA study)	Not specified	Rheumatoid Arthritis	Discontinued	Not specified	Not specified	Not specified	Not specified	Development for RA discontinued.	23

5.1 Focus Indication: Primary Immune Thrombocytopenia (ITP)

ITP is an autoimmune disorder where the immune system produces autoantibodies that target platelets and/or their precursor cells, megakaryocytes. This leads to increased platelet destruction and often impaired platelet production, resulting in thrombocytopenia (low platelet count) and an elevated risk of bleeding.[6] Symptoms can range from minor bruising and petechiae to severe, life-threatening hemorrhages. Fatigue and impaired quality of life are also common. A significant proportion of patients, estimated around 20%, become refractory to or have an inadequate response to existing first- and second-line therapies (e.g., corticosteroids, thrombopoietin receptor agonists, rituximab), highlighting a substantial unmet medical need for novel, effective, and well-tolerated treatments.[6] Mezagitamab, by depleting autoantibody-producing plasma cells and plasmablasts, aims to address the underlying autoimmune process in ITP.

Clinical Trial NCT04278924 (Phase 2b, TAK-079-1004):

This pivotal Phase 2b study was designed as a randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and efficacy of mezagitamab in adult patients with persistent (duration 3-12 months) or chronic (duration >1 year) primary ITP.6 Participants had previously failed or were intolerant to at least one first-line and one second-line ITP therapy.19 The trial evaluated three subcutaneous (SC) doses of mezagitamab (100 mg, 300 mg, and 600 mg) administered once weekly (QW) for 8 weeks, compared to placebo. Patients continued their stable background ITP treatments. The study enrolled 41 participants.24 The primary endpoint focused on safety and tolerability, while key secondary efficacy endpoints included various measures of platelet response.14

Key Efficacy Results (from topline announcements and ISTH 2024 presentation 6):

Mezagitamab demonstrated a clear, dose-dependent improvement in platelet counts compared to placebo.

Platelet Response: All tested doses of mezagitamab resulted in a higher platelet response rate than placebo. The increase in platelet counts was rapid and was sustained post-therapy, with therapeutic platelet levels (≥50,000/µL) maintained for at least 8 weeks after the last dose (up to Week 16).
600 mg Dose Cohort (ISTH 2024): This dose showed the most robust efficacy:
Complete Platelet Response (platelet count ≥100,000/µL): Achieved by 81.8% of patients.
Clinically Meaningful Platelet Response (platelet count ≥50,000/µL, a common therapeutic target): Achieved by 90.9% of patients.
Hemostatic Platelet Response (platelet count ≥30,000/µL and at least a 2-fold increase from baseline, indicating a level sufficient to prevent most spontaneous bleeding): Achieved by 100% of patients.

Safety and Tolerability Findings (NCT04278924, ISTH 2024 14):

The safety profile of mezagitamab in this ITP trial was reported as favorable and consistent with previous studies, with no new safety signals emerging.

Bleeding Events: A notable finding was a reduction in disease activity-related bleeding adverse events in mezagitamab-treated patients (17.9%) compared to placebo-treated patients (46.2%).
Treatment-Emergent Adverse Events (TEAEs):
TEAEs leading to discontinuation: 14.3% in mezagitamab arms vs. 0% in placebo.
Grade ≥3 TEAEs: 17.9% in mezagitamab arms vs. 23.1% in placebo.
Serious Adverse Events (SAEs): 14.3% in mezagitamab arms vs. 7.7% in placebo.

The positive efficacy, particularly the high response rates and sustained platelet counts with the 600 mg dose, coupled with a manageable safety profile, strongly supported the advancement of mezagitamab into Phase 3 development for ITP. The rapid and sustained nature of the platelet response is particularly encouraging, suggesting a potential disease-modifying effect rather than merely transient platelet elevation. While the overall safety was favorable, the higher rate of TEAEs leading to discontinuation in the mezagitamab arms compared to placebo warrants further investigation in larger Phase 3 trials to fully characterize the benefit-risk profile.

Table 4: Summary of Efficacy Results for Mezagitamab in Primary Immune Thrombocytopenia (NCT04278924 - Phase 2b, ISTH 2024 Data for 600mg dose)

Endpoint	Mezagitamab 600mg SC QW (n=~11-12 based on randomization ratios)	Placebo	Source Snippet(s)
Complete Platelet Response (≥100,000/µL)	81.8%	Not specified, but lower than mezagitamab arms	14
Clinically Meaningful Platelet Response (≥50,000/µL)	90.9%	Not specified, but lower than mezagitamab arms	14
Hemostatic Platelet Response (≥30,000/µL and ≥2x baseline)	100%	Not specified, but lower than mezagitamab arms	14
≥1 Disease Activity-Related Bleeding AE	17.9%	46.2%	14

Note: Specific patient numbers per arm for the ISTH 2024 presentation were not fully detailed in snippets, but overall trial enrolled 41 patients. Response rates for placebo and lower doses were generally stated as lower than the 600mg arm.

Phase 3 Trial in ITP (NCT06722235 / TAK-079-3002):

Based on the encouraging Phase 2b results, Takeda has initiated a global Phase 3 program for mezagitamab in adults with chronic primary ITP.9

Design: This is a randomized, double-blind, placebo-controlled study. Eligible participants are adults (≥18 years) with primary ITP for at least 12 months who have had an insufficient response or intolerance to at least two prior standard ITP therapies.[12] The estimated enrollment is 171 participants.
Intervention: Subcutaneous mezagitamab versus placebo. The specific dosing regimen for Phase 3 will be based on Phase 2b findings, likely focusing on higher, more effective doses. One description mentioned a regimen of QW for 8 weeks, 8 weeks off, then 8 more QW doses, but this may be subject to final protocol design.[19]
Primary Endpoint: Percentage of participants achieving a durable platelet response, typically assessed up to Week 24.[12]
Secondary Endpoints: Include cumulative number of weeks with platelet counts ≥50,000/µL and ≥30,000/µL, time to first platelet count ≥50,000/µL, complete platelet response, use of rescue therapy, incidence of bleeding events, changes in ITP-PAQ symptom scores, PK, and immunogenicity.[12]
Timeline and Regions: The trial is actively recruiting, with an estimated study completion around December 2027 to January 2028. It is a global trial, including sites in Japan and China.[10]

Continuation/Open-Label Extension (OLE) Studies:

Participants from both NCT04278924 and the ongoing NCT06722235 trial may be eligible to enroll in long-term OLE studies (e.g., NCT06948318, planned for August 2025) to assess the long-term safety, efficacy, and PK of mezagitamab.10 These studies will provide valuable data on the durability of response and the safety of prolonged exposure.

5.2 Other Investigated Indications

Mezagitamab's mechanism of action targeting CD38+ cells has prompted its investigation in several other autoimmune and hematologic conditions.

Myasthenia Gravis (MG):

Generalized MG is an autoimmune disorder typically caused by autoantibodies against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK) at the neuromuscular junction, leading to fluctuating muscle weakness.

Phase 2 Trial (NCT04159805 / EudraCT 2019-003383-47 / TAK-079-1005): This randomized, double-blind, placebo-controlled study evaluated SC mezagitamab (300 mg or 600 mg) or placebo administered QW for 8 weeks to 36 adults with generalized MG on stable background therapy. The trial has been completed.[15]
Primary Endpoint: Safety and tolerability.
Efficacy Results:
Myasthenia Gravis Composite (MGC) scale score showed a statistically significant improvement from baseline at Week 8 for the 300 mg mezagitamab group compared to placebo (mean change: -7.4 vs -5.5; p=0.005). The 600 mg group did not show a significant difference from placebo on this measure (-2.4 vs -5.5; p=0.13).
Anti-AChR antibody levels also showed a statistically significant reduction from baseline at Week 8 in the 300 mg group compared to placebo (mean change: -39.386 vs -7.731 nmol/L; p=0.005). The 600 mg group did not show a significant difference (-5.668 vs -7.731 nmol/L; p=0.215).
Other efficacy scales (MG-ADL, QMG, MG-QoL15r) showed numerical improvements, particularly with the 300 mg dose, but these did not consistently reach statistical significance against placebo, possibly due to the small sample size (12 patients per arm).
Safety: TEAEs were reported in 66.7% (placebo), 75.0% (300 mg), and 91.7% (600 mg) of participants. SAEs occurred in 8.3% of participants in each group. No discontinuations due to AEs were reported.[15] The results suggest that the 300 mg SC QW dose of mezagitamab may offer clinical benefits in MG, supported by reductions in anti-AChR antibody levels and improvements in the MGC score. The lack of a clear dose-response with the 600 mg arm on some measures warrants further investigation, potentially related to inter-patient variability or the sensitivity of the endpoints in this relatively small study.

Multiple Myeloma (MM):

MM is a hematologic malignancy characterized by the proliferation of malignant plasma cells that express high levels of CD38.

Phase 1b Study in Relapsed/Refractory MM (RRMM) (NCT03439280): This dose-escalation study evaluated SC mezagitamab (45 mg, 135 mg, 300 mg, 600 mg fixed doses) in heavily pretreated RRMM patients (≥3 prior lines, refractory to PI and IMiD).[10]
Efficacy (as of June 14, 2019, for 14 patients with ≥4 cycles): The Objective Response Rate (ORR, ≥Partial Response) was 43%. The Clinical Benefit Rate (CBR, ≥Minimal Response) was 57%. In patients naive to prior anti-CD38 therapy, the ORR was 46%.
Pharmacodynamics: Dose-dependent saturation of CD38 and depletion of bone marrow myeloma cells were observed, with maximal effects at the 300 mg dose.
Safety: Mezagitamab SC was well-tolerated. No dose-limiting toxicities (DLTs) were identified, and the MTD was not reached. Notably, no ≥Grade 1 systemic infusion-related reactions (IRRs) were reported. Only one Grade 1 injection site reaction (pruritus) occurred in over 500 injections. Drug-related AEs (any grade, in ≥3 patients) included fatigue (14%) and anemia (11%). There was no drug-related ≥Grade 1 lymphopenia or thrombocytopenia. One drug-related Grade 2 upper respiratory tract infection (4%) and two drug-related Grade 3 AEs (decreased neutrophil count and anemia, one patient each, 7% total) were observed. No drug-related Grade 4 AEs, SAEs, or discontinuations due to AEs were reported. The preliminary data in RRMM are promising, showing clinically relevant activity with SC mezagitamab as a single agent in a heavily pretreated population. The safety profile, particularly the absence of IRRs and significant hematologic toxicities common with other anti-CD38 mAbs, along with the convenience of SC administration (≤1 minute injection volume of 2 mL), suggests a favorable therapeutic index and potential for home-based administration.

Systemic Lupus Erythematosus (SLE):

SLE is a chronic, multisystem autoimmune disease driven by autoantibody production and immune complex deposition.

Phase 1b/2 Study: This study evaluated mezagitamab (45 mg, 90 mg, or 135 mg SC Q3W for 12 weeks) or placebo in 22 adult patients with moderate to severe SLE (SLEDAI-2K ≥6, positive autoantibodies).[8]
Efficacy: Responder analyses for CLASI (cutaneous lupus) and SLEDAI-2K (systemic activity) did not reveal observable differences across treatment groups. However, a trend for more profound skin responses (CLASI) was noted in patients with higher baseline CLASI scores (>10).
Pharmacodynamics: Median CD38 RO on NK cells was up to 88.4% with concurrent NK cell depletion up to 90% (135 mg group). However, mean reductions in total IgG and specific autoantibodies (anti-dsDNA, anti-ENA) were modest (<20%) in all dose groups. CyTOF and type 1 IFN gene signature analyses suggested a "broad immune landscape shift."
Safety: Mezagitamab was well tolerated, with AEs balanced across treatment groups and no TEAEs exceeding Grade 2. In SLE, the clinical efficacy signal was not definitive with the Q3W regimen over 12 weeks, despite clear PD effects on NK cells. The limited impact on autoantibody levels may suggest that this regimen was insufficient to achieve robust clinical responses or that the targeted cell populations (long-lived plasma cells) were not adequately depleted. The "broad immune landscape shift" is an area for further research.

IgA Nephropathy (IgAN):

IgAN is a common form of glomerulonephritis characterized by IgA deposition in the glomeruli, leading to kidney damage.

Phase 1/2 Trial (NCT05174221 / TAK-079-1006): This ongoing study is evaluating SC mezagitamab in adults with primary IgAN on stable supportive care. It consists of an initial treatment period (QW for 8 weeks, then Q2W for 16 weeks) followed by a follow-up and potential long-term extension with retreatment.[10] Enrollment of 16 participants is complete, and the study is active but not recruiting, with an estimated completion date of March 2026.
Primary Endpoint: Safety and tolerability.
Secondary Endpoints: PK (Ctrough), PD (serum IgA levels), efficacy (percent change in Urine Protein to Creatinine Ratio at Week 36), and ADA.
Planned Phase 3 Trial (NCT06963827): Takeda intends to initiate a Phase 3 trial in IgAN in August 2025, evaluating mezagitamab in combination with stable background therapy.[10] Targeting IgA-producing plasma cells/plasmablasts with mezagitamab is a rational therapeutic approach for IgAN. The ongoing Phase 1/2 study will provide essential safety, PK/PD, and preliminary efficacy data (particularly on proteinuria reduction) to inform the design and execution of the planned Phase 3 trial.

Rheumatoid Arthritis (RA):

Development of mezagitamab for RA appears to have been discontinued.23 The reasons for discontinuation are not detailed in the provided snippets but could relate to insufficient efficacy, safety concerns in this specific population, or strategic portfolio decisions by the developer.

5.3 Overall Efficacy Synthesis

Mezagitamab has demonstrated varying degrees of clinical activity across the indications studied. The most compelling efficacy signals to date are in ITP, where it induces rapid, dose-dependent, and sustained platelet responses, and in RRMM, where single-agent activity has been observed in heavily pretreated patients. In Myasthenia Gravis, the 300mg SC dose showed promise in reducing anti-AChR antibodies and improving MGC scores. The efficacy in SLE with the tested regimen was less apparent, despite evidence of target engagement on NK cells. The ongoing and planned trials in ITP and IgAN will be crucial in further defining its therapeutic role. A key emerging theme is the potential for sustained responses after treatment cessation, particularly noted in ITP, which could imply a disease-modifying effect rather than purely symptomatic relief. This is a significant area of interest, as many current therapies for autoimmune diseases require continuous administration to maintain efficacy.

6. Safety and Tolerability Profile

The safety and tolerability of mezagitamab have been assessed in healthy volunteers and in patients across various autoimmune and hematologic conditions. Generally, it has been reported as well-tolerated, particularly with subcutaneous administration.

Healthy Volunteers (Phase 1, Single Ascending Dose Study) [5]:

Mezagitamab was well tolerated at IV doses up to 0.06 mg/kg and SC doses up to 0.6 mg/kg.
All adverse events (AEs) were mild or moderate in intensity.
No serious adverse events (SAEs), deaths, or withdrawals due to AEs were reported.
Infusion/Injection Site Reactions: No infusion reactions (IRRs) were observed with IV administration. Mild, transient injection site reactions (ISRs) were noted after SC injections, mostly resolving within 7 days, and these showed an inverse dose-effect relationship (less frequent or severe at higher SC doses).
Cytokine Release Syndrome (CRS): Mild CRS was observed in some subjects, primarily at higher doses and more frequently with IV administration (7 subjects) than SC (3 subjects). Symptoms coincided with reductions in plasmablasts and NK cells and were associated with moderate, transient increases in cytokines (e.g., TNF-α, IL-1α, IL-6) and C-reactive protein. SC administration resulted in minimal cytokine level increases compared to IV.
Hematologic Safety: No anemia, thrombocytopenia, or significant lymphopenia was reported. This is a notable finding compared to some other anti-CD38 antibodies.
Immunoglobulin Levels: Reductions in total serum IgA, IgG, and IgM levels (15–60%) were observed, particularly with SC doses ≥0.1 mg/kg. Recovery was slow, with levels not returning to baseline within 78 days for doses ≥0.3 mg/kg SC.

Primary Immune Thrombocytopenia (ITP) Patients (Phase 2b, NCT04278924 - ISTH 2024 data) [14]:

Overall Safety: Favorable safety profile, consistent with previous studies; no new safety signals identified.
Bleeding Events: Fewer patients treated with mezagitamab experienced ≥1 disease activity-related bleeding AE compared to placebo (17.9% vs. 46.2%).
TEAEs leading to discontinuation: 14.3% in mezagitamab arms vs. 0% in placebo.
Grade ≥3 TEAEs: 17.9% in mezagitamab arms vs. 23.1% in placebo.
SAEs: 14.3% in mezagitamab arms vs. 7.7% in placebo.

Myasthenia Gravis (MG) Patients (Phase 2, NCT04159805) [15]:

TEAEs: Occurred in 66.7% (placebo), 75.0% (300 mg mezagitamab), and 91.7% (600 mg mezagitamab) of participants.
SAEs: Reported in 8.3% of participants in each of the three groups. Specific SAEs included MG exacerbation (one in 600 mg arm, not treatment-related), enteritis (one in placebo, not treatment-related), suicidal ideation (one in 300 mg arm, not treatment-related), and gastroenteritis (one in placebo, not treatment-related).
Discontinuations due to AEs: None reported in any group.
Common Non-Serious AEs (≥5% frequency): Chills and pyrexia were more common in the 600 mg group. Nasopharyngitis was reported in both placebo and 600 mg groups. Other AEs were generally balanced or sporadic.

Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Phase 1b) [16]:

Overall Safety: Well-tolerated with SC administration.
IRRs/ISRs: No ≥Grade 1 systemic IRRs. One Grade 1 ISR (pruritus) in >500 injections.
Drug-related AEs (any grade, ≥3 patients): Fatigue (14%), anemia (11%).
Hematologic Safety: No drug-related ≥Grade 1 lymphopenia or thrombocytopenia.
Infections: One drug-related Grade 2 upper respiratory tract infection (4%).
Grade 3 Drug-related AEs: Decreased neutrophil count (1 patient), anemia (1 patient) (7% total).
Serious/Severe AEs: No drug-related Grade 4 AEs, SAEs, or AEs leading to discontinuation or death.

Systemic Lupus Erythematosus (SLE) Patients (Phase 1b/2) [8]:

Mezagitamab was well tolerated.
AEs were balanced across treatment groups.
No TEAEs exceeding Grade 2 were reported.

General Safety Considerations:

Immunoglobulin Depletion: A consistent pharmacodynamic effect is the reduction of serum immunoglobulins, particularly with sustained SC dosing. While this is part of the therapeutic mechanism in autoantibody-mediated diseases, prolonged or excessive hypogammaglobulinemia can increase the risk of infections. Long-term monitoring of Ig levels and infection rates will be critical.
Immunogenicity: Anti-drug antibodies (ADAs) are monitored in clinical trials, but detailed incidence and clinical impact are not consistently reported across all snippets for patient populations.
Subcutaneous Administration: The SC route generally appears to be associated with good local tolerability and a lower risk of systemic reactions like CRS compared to IV administration in early studies.

The overall safety profile of mezagitamab, especially its SC formulation, appears promising. The low rates of severe IRRs and significant hematologic toxicities (lymphopenia, thrombocytopenia) are notable potential advantages over some existing anti-CD38 therapies. However, the observed reduction in immunoglobulins and the TEAEs leading to discontinuation in the ITP trial (though the rate was not alarmingly high and needs context of specific AEs) require careful evaluation in ongoing and future Phase 3 studies to fully delineate the long-term benefit-risk balance.

Table 5: Summary of Key Adverse Events Reported for Mezagitamab (Across Select Trials)

Indication/Study	Mezagitamab Dose Group(s)	Comparator	Adverse Event Category	Frequency/Percentage	Source Snippet(s)
Healthy Volunteers (Phase 1)	IV up to 0.06 mg/kg; SC up to 0.6 mg/kg	Placebo	All AEs	Mild or Moderate	5
			SAEs/Deaths/Withdrawals due to AEs	None	5
	IV		Infusion Reactions	None	5
	SC		Injection Site Reactions	Mild, transient, inverse dose-effect	5
	IV > SC		Mild CRS	More with IV, higher doses	5
ITP (Phase 2b, NCT04278924)	100, 300, 600 mg SC QW	Placebo	Disease-Related Bleeding AEs (≥1)	17.9% (Mezagitamab) vs 46.2% (Placebo)	14
			TEAEs leading to Discontinuation	14.3% (Mezagitamab) vs 0% (Placebo)	14
			Grade ≥3 TEAEs	17.9% (Mezagitamab) vs 23.1% (Placebo)	14
			SAEs	14.3% (Mezagitamab) vs 7.7% (Placebo)	14
MG (Phase 2, NCT04159805)	300mg, 600mg SC QW	Placebo	Any TEAE	75.0% (300mg), 91.7% (600mg) vs 66.7% (Placebo)	15
			SAEs	8.3% (All groups)	15
			Discontinuation due to AEs	None (All groups)	15
RRMM (Phase 1b)	45-600mg SC	Single-agent	Drug-related Fatigue (any grade)	14%	16
			Drug-related Anemia (any grade)	11%	16
			Drug-related ≥Grade 1 Lymphopenia/Thrombocytopenia	None reported	16
			Drug-related Grade 3 Neutropenia / Anemia	1 patient each (7% total)	16
SLE (Phase 1b/2)	45, 90, 135mg SC Q3W	Placebo	TEAEs	Balanced across groups, none > Grade 2	8

7. Regulatory Status and Designations

Mezagitamab has garnered attention from regulatory agencies, reflected in several special designations aimed at facilitating its development for conditions with unmet medical needs.

U.S. Food and Drug Administration (FDA):

Orphan Drug Designation:
For the treatment of Immune Thrombocytopenia (ITP), granted on September 8, 2023.[1]
For the treatment of Myasthenia Gravis, granted on October 17, 2022.[1] Orphan Drug Designation is granted to therapies intended for rare diseases or conditions (affecting fewer than 200,000 people in the U.S.), providing incentives such as tax credits for clinical trials, exemption from user fees, and potential for 7 years of market exclusivity upon approval.
Fast Track Designation:
For the treatment of chronic/persistent ITP.[1] Fast Track Designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. Benefits include more frequent meetings with the FDA, eligibility for accelerated approval and priority review if relevant criteria are met, and the possibility of a rolling review.
Approval Status: As of the latest available information, mezagitamab is not yet FDA approved for any indication.[34]

European Medicines Agency (EMA):

While no specific marketing authorization or formal opinions for mezagitamab were found in the provided materials, its clinical development includes European sites and registration with EudraCT numbers. For example, the Phase 2 MG trial (EudraCT 2019-003383-47) [15], the Phase 1/2 IgAN trial (EudraCT 2021-005023-20) [13], and the planned/ongoing Phase 3 ITP trials (EU CTIS 2024-514401-54-00; EUCT2025-520825-19-00 for IgAN; EUCT2025-521692-31-00 for ITP OLE) [10] all indicate active regulatory engagement within Europe. The presence of these registrations is standard for drugs intended for potential marketing authorization in the EU.

Pharmaceuticals and Medical Devices Agency (PMDA), Japan:

Similar to the EMA, no specific marketing authorization or formal opinions from the PMDA were identified.
However, Takeda is conducting or planning clinical trials in Japan for ITP (Phase 3, NCT06722235 / jRCT2031240667) [10] and IgA Nephropathy (Phase 1/2, NCT05174221 / jRCT2011220009).[10] This clinical activity, often registered with jRCT numbers, is a prerequisite for seeking PMDA approval.

Table 6: Regulatory Designations and Status for Mezagitamab

Regulatory Agency	Designation/Status	Indication	Date Granted / Status Date	Source Snippet(s)
FDA (USA)	Orphan Drug Designation	Immune Thrombocytopenia (ITP)	September 8, 2023	1
FDA (USA)	Orphan Drug Designation	Myasthenia Gravis	October 17, 2022	1
FDA (USA)	Fast Track Designation	Chronic/Persistent ITP	Not specified, but active	1
FDA (USA)	Approval Status	Any	Not FDA Approved	34
EMA (Europe)	Clinical Trial Registrations (EudraCT/EU CTIS)	MG, IgAN, ITP	Various (ongoing development)	10
PMDA (Japan)	Clinical Trial Registrations (jRCT)	ITP, IgAN	Various (ongoing development)	10

8. Developer and Manufacturing Information

8.1 Key Developers

The development of mezagitamab involves a collaboration of multiple entities:

Takeda Pharmaceutical Company Limited (and its subsidiaries like Millennium Pharmaceuticals, Inc. and Takeda Development Center Americas, Inc.) is the primary entity responsible for the clinical development and potential future commercialization of mezagitamab.[4]
BioInvent International AB is credited with the initial discovery of the antibody through its proprietary n-CoDeR® antibody library.[4]
XOMA Corporation plays a role in the licensing chain, holding rights related to BioInvent's library and XOMA's bacterial protein expression technology, through which Takeda obtained a sublicense to the antibody.[4]

8.2 Formulation and Administration

Mezagitamab is formulated as a liquid solution intended for subcutaneous (SC) injection.[2]

Production: The antibody is produced in Chinese Hamster Ovary (CHO) cells, a common host system for recombinant therapeutic proteins.[2]
Purification: Protein A chromatography is utilized for purification, a standard method for monoclonal antibodies.[2]
Concentration: Specific concentrations of the final drug product are typically detailed on vial labels or in prescribing information once approved; current snippets refer to "See label" [2] or provide details for reconstitution if supplied as a lyophilized powder, though mezagitamab is generally described as a liquid. The Phase 1b MM study noted a maximum SC injection volume of 2 mL.[16]

The development of an SC formulation is a significant aspect, offering potential advantages in terms of patient convenience (e.g., potential for self-administration or easier administration in outpatient settings) and possibly an improved tolerability profile regarding systemic reactions compared to intravenous infusions of other anti-CD38 therapies.

8.3 Dosage Information from Clinical Trials

The dosage of mezagitamab has varied across clinical trials, reflecting dose-finding efforts and different therapeutic intensities required for various indications:

Healthy Volunteers (Phase 1): IV doses up to 0.06 mg/kg; SC doses up to 0.6 mg/kg.[5]
ITP (Phase 2b, NCT04278924): Fixed SC doses of 100 mg, 300 mg, and 600 mg administered once weekly (QW) for 8 weeks.[6]
ITP (Phase 3, NCT06722235): The specific dose is based on Phase 2b results. One description for a Phase 3 trial mentions SC QW for 8 weeks, then 8 weeks off, followed by 8 more QW doses, though this may be for a specific arm or an earlier plan.[19]
Myasthenia Gravis (Phase 2, NCT04159805): Fixed SC doses of 300 mg and 600 mg QW for 8 weeks.[15]
Multiple Myeloma (Phase 1b, RRMM): Fixed SC doses of 45 mg, 135 mg, 300 mg, and 600 mg, administered QW for 8 doses, then every other week (Q2W) for 8 doses, then monthly.[16]
SLE (Phase 1b/2): Fixed SC doses of 45 mg, 90 mg, and 135 mg administered every 3 weeks (Q3W) for 12 weeks.[8]
IgA Nephropathy (Phase 1/2, NCT05174221): SC administration QW for 8 weeks, then Q2W for 16 weeks.[13]

The use of fixed doses in later-phase patient trials (e.g., up to 600 mg SC) contrasts with the weight-based (mg/kg) dosing in the initial healthy volunteer study. This transition to fixed dosing is common in antibody development as it simplifies administration in clinical practice. The wide range of doses and frequencies tested across indications underscores the process of optimizing the therapeutic regimen for each specific disease context.

9. Discussion and Future Outlook

Mezagitamab (TAK-079) has emerged as a promising investigational anti-CD38 monoclonal antibody with a distinct subcutaneous administration route and a mechanism aimed at depleting pathogenic CD38-expressing cells. Its development program spans several autoimmune diseases and hematologic malignancies, with Primary Immune Thrombocytopenia (ITP) being the most advanced indication.

Therapeutic Potential and Differentiation:

The therapeutic potential of mezagitamab is most evident in ITP, where Phase 2b results demonstrated rapid, dose-dependent, and, importantly, sustained platelet responses, particularly at the 600 mg SC QW dose.6 This has led to the initiation of global Phase 3 trials. The possibility of achieving durable responses that persist after treatment cessation is a key area of interest, as this could signify a disease-modifying effect rather than mere transient platelet support, a significant advancement for ITP patients.

In Relapsed/Refractory Multiple Myeloma (RRMM), early Phase 1b data showed encouraging single-agent activity (43% ORR in heavily pretreated patients) with a notably favorable safety profile, especially the absence of infusion-related reactions and low rates of severe hematologic toxicity.[16] This, combined with the convenience of SC administration, could position mezagitamab as a valuable alternative or addition to existing MM therapies, pending further data.

For Myasthenia Gravis, the 300 mg SC QW dose demonstrated statistically significant improvements in the Myasthenia Gravis Composite (MGC) score and reductions in anti-AChR antibody levels in a Phase 2 study.[15] While other endpoints were not consistently met, these signals warrant further investigation, potentially with optimized dosing or in specific patient subgroups.

The development in Systemic Lupus Erythematosus (SLE) showed less clear clinical efficacy with the Q3W regimen tested, despite pharmacodynamic evidence of NK cell depletion and receptor occupancy.[8] The modest impact on autoantibody levels (<20% reduction) suggests that alternative dosing strategies or patient selection criteria might be necessary to unlock its potential in this complex disease. The ongoing Phase 1/2 study in IgA Nephropathy, targeting IgA-producing plasma cells, is based on a strong mechanistic rationale and will provide important insights.[10]

A primary differentiating factor for mezagitamab is its subcutaneous formulation, which offers enhanced patient convenience and has been associated with a favorable tolerability profile, including a low incidence of injection site reactions and, notably in early studies, a lower risk of systemic cytokine release syndrome compared to IV administration.[5] Furthermore, its potentially more selective binding to CD38 on target pathogenic cells versus erythrocytes and platelets [16] could translate to a better hematologic safety profile, a significant clinical advantage if borne out in larger trials.

Unmet Needs Addressed:

Mezagitamab aims to address significant unmet needs across its target indications. In ITP, it offers a novel mechanism for patients refractory to or intolerant of existing therapies, with the potential for durable remission.6 In MG and SLE, it represents a targeted approach to deplete autoantibody-producing cells. For MM, an effective and well-tolerated SC anti-CD38 option would be a welcome addition. In IgAN, it offers a novel immunomodulatory strategy.

Ongoing and Future Research:

The successful completion and outcomes of the Phase 3 trials in ITP (NCT06722235 and associated OLEs) are paramount for mezagitamab's trajectory. Data from the Phase 1/2 IgAN study (NCT05174221) will inform the planned Phase 3 trial in this indication. Further exploration in MM, likely in combination with other agents, may also be pursued. Critical long-term data will revolve around the durability of responses, the impact of sustained immunoglobulin depletion on infection risk, and the overall long-term safety profile across diverse patient populations.

Potential Challenges:

The competitive landscape, particularly in MM where other anti-CD38 antibodies are well-established (albeit mostly IV), presents a challenge. Mezagitamab will need to clearly demonstrate differentiated efficacy, safety, or convenience to gain significant market share. Navigating the regulatory pathways for multiple indications across different global agencies (FDA, EMA, PMDA) is a complex undertaking. Furthermore, fully understanding and managing the long-term consequences of CD38+ cell depletion, including the extent and clinical significance of hypogammaglobulinemia and any potential impact on broader immune competence, will be essential. The variable efficacy signals seen in SLE highlight the need for careful patient selection and potentially tailored regimens for different autoimmune conditions.

Broader Implications:

The successful development of mezagitamab would further solidify CD38 as a key therapeutic target in a broader array of autoimmune and hematologic disorders. It would also underscore the value of SC formulations for monoclonal antibodies in improving patient experience and potentially enhancing tolerability. The pharmacodynamic insights gained from studying mezagitamab's effects on various immune cell subsets (plasmablasts, plasma cells, NK cells, T cells) and immunoglobulin levels across different diseases will contribute significantly to our understanding of CD38 biology and the immunopathology of these conditions. The observation of sustained clinical benefit after treatment cessation in ITP, if confirmed in Phase 3, could herald a shift towards therapies aiming for immune reset rather than continuous suppression.

A critical aspect for long-term management will be to determine if the observed reductions in total immunoglobulin levels, particularly with prolonged or repeated dosing, translate into a clinically significant increased risk of infections. This will necessitate robust long-term safety follow-up and may require guidelines for monitoring Ig levels and considering prophylactic measures (e.g., immunoglobulin replacement therapy) in susceptible individuals, a common consideration for potent B-cell or plasma cell depleting therapies.

10. Conclusions

Mezagitamab (TAK-079) is a subcutaneously administered, fully human anti-CD38 monoclonal antibody with a multifaceted mechanism of action involving depletion of CD38-expressing cells and enzymatic inhibition. Its development program, led by Takeda, is actively progressing across several indications.

The most compelling data to date comes from the Phase 2b study in Primary Immune Thrombocytopenia (NCT04278924), where mezagitamab demonstrated dose-dependent, rapid, and sustained platelet responses, particularly with the 600 mg SC QW dose. These positive findings, coupled with a generally favorable safety profile, have supported its advancement into global Phase 3 trials (NCT06722235), positioning ITP as the lead indication. The potential for durable off-treatment responses in ITP is a particularly noteworthy feature that could offer a significant clinical advantage.

In other indications, mezagitamab has shown early promise. Phase 1b results in Relapsed/Refractory Multiple Myeloma indicated good single-agent activity and excellent tolerability, including a lack of infusion-related reactions. Phase 2 data in Myasthenia Gravis suggested clinical and serological benefits with the 300 mg SC dose. The development in IgA Nephropathy is advancing based on a strong mechanistic rationale. However, clinical efficacy in Systemic Lupus Erythematosus was less clear in the initial Phase 1b/2 study with the regimen tested, despite observed pharmacodynamic effects.

Key differentiating attributes of mezagitamab include its subcutaneous route of administration, which enhances convenience, and a safety profile that, based on available data, appears to be favorable, with notably low rates of severe infusion/injection site reactions and certain hematologic toxicities that can be challenging with other CD38-targeted therapies. Regulatory agencies have recognized its potential, granting Orphan Drug Designations for ITP and Myasthenia Gravis, and Fast Track Designation for chronic/persistent ITP by the FDA.

Future research will focus on the pivotal Phase 3 outcomes in ITP, further results from the IgAN program, and potentially further exploration in MM. Long-term safety, particularly concerning the effects of sustained immunoglobulin depletion and the risk of infections, will remain a key area of assessment. If ongoing and future trials confirm its efficacy and safety, mezagitamab could become a valuable therapeutic option for patients with ITP and potentially other CD38-mediated diseases, offering a convenient, well-tolerated, and possibly disease-modifying treatment.

References

(Based on cited snippet IDs in the report body)

25 DrugBank. (n.d.). Idiopathic Thrombocytopenic Purpura Recruiting Phase 3 Trials for Mezagitamab (DB16370). DrugBank Online.

35 DrugBank. (n.d.). Primary Immune Thrombocytopenia Active Not Recruiting Phase 2 Trials for Mezagitamab (DB16370). DrugBank Online.

2 ApexBio. (n.d.). Anti-CD38 Antibody (Mezagitamab).

3 MedChemExpress. (n.d.). Mezagitamab.

7 National Cancer Institute. (n.d.). Definition of anti-CD38 monoclonal antibody TAK-079. NCI Drug Dictionary.

5 Fedyk, E. R., et al. (2020). Tolerability, pharmacokinetics and pharmacodynamics of TAK‐079, a human anti‐CD38 monoclonal antibody, in healthy subjects. British Journal of Clinical Pharmacology, 86(7), 1329-1339. (Accessed via PMC7319013)

9 BioInvent. (2025, April 8). BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3.

4 BioSpace. (2025, April 8). BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3.

12 Takeda Clinical Trials. (n.d.). A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (NCT06722235).

13 Takeda Clinical Trials. (n.d.). A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy (NCT05174221).

19 Veeva CTV. (n.d.). A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (NCT04278924 Continuation Information).

6 Takeda. (2024, March 13). Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia.

28 Open Targets Platform. (n.d.). Mezagitamab (CHEMBL4297833) Clinical Trials.

10 PatSnap Synapse. (n.d.). Mezagitamab Drug Profile.

34 U.S. Food and Drug Administration. (2022, October 17). Orphan Drug Designations and Approvals: Mezagitamab for Myasthenia Gravis.

1 Orpha.net. (n.d.). Mezagitamab.

3 MedChemExpress. (n.d.). Mezagitamab (TAK-079) for ITP. (Product page, not a clinical trial publication)

26 Carebox Health. (n.d.). A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (NCT06722235 OLE).

8 Werth, V. P., et al. (2024). Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Science & Medicine, 11(1), e001112. (Accessed via BMJ Lupus)

6 Takeda. (2024, March 13). Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079)...for Primary Immune Thrombocytopenia. 6

14 HCP Live. (2024, June 25). Mezagitamab Achieves Platelet Response, Favorable Safety in ITP Treatment.

15 EU Clinical Trials Register. (2023, April 19). Results for EudraCT 2019-003383-47 (TAK-079 in Myasthenia Gravis).

16 Fedyk, E., et al. (2019). Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb), in Patients with Relapsed Refractory Multiple Myeloma (RRMM). ResearchGate. (ASH 2018 Abstract Update/Poster)

30 SparkCures. (n.d.). Mezagitamab (TAK-079) Multiple Myeloma Overview.

33 Werth, V. P., et al. (2024, March 5). Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. PubMed. (PMID: 38453421)

8 Werth, V. P., et al. (2024). Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Science & Medicine, 11(1), e001112. 8

36 DelveInsight. (2025). Anti-CD38 antibody - Pipeline Insight, 2025.

1 Orpha.net. (n.d.). Mezagitamab Regulatory Status. 1

23 AdisInsight by Springer. (2025, May 14). Mezagitamab - Takeda.

24 Takeda Clinical Trials. (n.d.). A Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-079 in Participants With Primary Immune Thrombocytopenia (ITP) (TAK-079-1004 / NCT04278924).

17 FirstWord Pharma. (2024, June 27). Mezagitamab Shows Efficacy for Chronic, Persistent Primary Immune Thrombocytopenia in Phase 2 Trial (ISTH 2024).

6 Takeda. (2024, March 13). Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079)...for Primary Immune Thrombocytopenia. 6

15 EU Clinical Trials Register. (2023, April 19). Results for EudraCT 2019-003383-47 (TAK-079 in Myasthenia Gravis). 15

20 EU Clinical Trials Register. (n.d.). Search for 2019-003383-47. 15

16 Fedyk, E., et al. (2019). Preliminary Results from a Phase 1b Study of TAK-079...in Patients with...RRMM. ResearchGate. 16

31 ResearchGate. (n.d.). Publications by Deborah Berg (Related to MM). (Contextual, not direct Mezagitamab data)

10 PatSnap Synapse. (n.d.). Mezagitamab Clinical Trials. 10

29 ClinicalTrials.gov (via Takeda Protocol). (2021, February 3). Protocol for NCT04159805 (TAK-079 in Myasthenia Gravis).

18 Werth, V. P., et al. (2024). Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Science & Medicine, 11(1), e001112. 8

5 Fedyk, E. R., et al. (2020). Tolerability, pharmacokinetics and pharmacodynamics of TAK‐079...in healthy subjects. British Journal of Clinical Pharmacology. 5

27 Carebox Health. (n.d.). A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (OLE for NCT04278924/NCT06722235). 26

19 Veeva CTV. (n.d.). A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (NCT06722235). 12

15 EU Clinical Trials Register. (2023, April 19). Results for EudraCT 2019-003383-47 (TAK-079 in Myasthenia Gravis). 15

20 EU Clinical Trials Register. (n.d.). Search for 2019-003383-47. 15

3 MedChemExpress. (n.d.). Mezagitamab. 3

5 Fedyk, E. R., et al. (2020). Tolerability, pharmacokinetics and pharmacodynamics of TAK‐079...in healthy subjects. British Journal of Clinical Pharmacology. 5

7 National Cancer Institute. (n.d.). Definition of anti-CD38 monoclonal antibody TAK-079. NCI Drug Dictionary. 7

23 AdisInsight by Springer. (2025, May 14). Mezagitamab - Takeda. 23

12 Takeda Clinical Trials. (n.d.). A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (NCT06722235). 12

8 Werth, V. P., et al. (2024). Mezagitamab in systemic lupus erythematosus... Lupus Science & Medicine. 8

21 Takeda Clinical Trials. (n.d.). A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (NCT06722235). 12

9 BioInvent. (2025, April 8). BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3. 9

11 BioSpace. (2025, April 8). BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3.

22 Takeda Clinical Trials. (n.d.). A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (NCT06722235).